Monotherapy versus polytherapy of enoxaparin and hydroxychloroquine for the treatment of COVID-19: A randomized controlled clinical trial

Amira S. A. Said; Raghda R. Hussein; Doaa Mahmoud Khalil; Alzhraa M. Fahmy; Ahmed H.A. Hassanein; Lamiaa N. Abdelaty

Ayuda

Monotherapy versus polytherapy of enoxaparin and hydroxychloroquine for the treatment of COVID-19: A randomized controlled clinical trial

Amira S.A. Said ^[3] ; Raghda R.S. Hussein ^[1] ; Doaa Mahmoud Khalil ^[1] ; Alzhraa M. Fahmy ^[1] ; Ahmed H.A. Hassanein ^[1] ; Lamiaa N. Abdelaty ^[2]
1. [1] Beni-Suef University
  
  Beni-Suef University
  
  Egipto
2. [2] October 6 University
  
  October 6 University
  
  Egipto
3. [3] PhD. Department of Clinical Pharmacy, College of Pharmacy, Al Ain University, Al Ain, Abu Dhabi, UAE. Department of Clinical Pharmacy, Faculty of Pharmacy, Beni-Suef University, Egypt.
Mostrar afiliaciones +
Localización: Pharmacy Practice (Granada), ISSN-e 1886-3655, Vol. 21, Nº. 1, 2023 (Ejemplar dedicado a: Jan-Mar)
Idioma: inglés
Enlaces
- Texto completo (pdf)
Resumen
- Objectives: The current study aims to assess the efficacy and safety of Enoxaparin and hydroxychloroquine (HCQ) used as monothrapy or polytherapy versus standard care alone in Coronavirus 2019 (COVID-19) infected patients. Methods: The current study included two hundred patients with laboratory confirmed COVID-19 infection. Patients admitted to hospital were randomly allocated into four groups: group I: received standard COVID-19 therapy, group II: received Enoxaparin 40mg/day subcutaneously (SC) plus standard therapy, group III: received 400 mg/day HCQ plus standard therapy & group IV: received a combination of 400 mg/day HCQ and Enoxaparin plus standard COVID-19 therapy. The disease progression was evaluated by duration to a negative polymerase chain reaction (PCR), length of hospital or Intensive Care Unit (ICU) stay, and mortality rate. The safety of treatments was evaluated by measuring adverse effects. Results: The length of hospital stay, ICU admission and mortality were significantly decreased in Enoxaparin plus standard COVID-19 therapy group versus other groups. Conclusion: These findings suggest that Enoxaparin was safe, effective, and well tolerated and has a role in decreasing the progression of the disease and its complications while HCQ did not discover any evidence of extra therapeutic benefits.